April 30, 2021 -- Qiagen has announced the upcoming launch of the EZ2 Connect product line, an automated sample-processing platform that aims to benefit biomedical research, forensics, and clinical diagnostics.
EZ2 Connect instruments use prefilled cartridges and magnetic bead technology to process up to 24 samples in parallel in as little as 20 minutes, ensuring process safety and efficiency of nucleic acid extraction. The new platform builds on Qiagen's EZ1 instrument line, which saw more than 4,500 devices installed worldwide at the end of 2020.
The EZ2 Connect platform will be tailored to three different key versions. The EZ2 Connect for use in research and pharmaceutical laboratory and the EZ2 Connect Fx for use in forensics and human identification will be launched in July. The release of the EZ2 Connect MDx for use in molecular diagnostic workflows is planned for early 2022, with regulatory approval in the U.S., the EU, and other markets worldwide.